An Alert Naming Inventory in Weeks
The American Society of Clinical Oncology has warned that some oncology practices have less than a few weeks of ifosfamide on hand, describing "critical supply disruptions" of a chemotherapy drug for which no direct substitute is available. The society published the warning through its policy news channel.
The alert, reported by OncLive, moves this from a statistical entry on a shortage list to an operational problem with a countdown attached. A practice with three weeks of inventory and patients on a treatment cycle has a scheduling decision to make, not a policy concern.
MedicalDaily previously reported that active U.S. drug shortages climbed to 227 in the second quarter, with ifosfamide named among the emerging scarcities. What has changed since is the severity at the practice level and the arrival of a formal professional society alert.
The FDA first added ifosfamide injection to its shortage database on June 12 and continues to list it. The agency attributes the disruption to requirements related to complying with good manufacturing practices at Baxter Healthcare, combined with increased demand pressure on Fresenius Kabi USA and Hikma Pharmaceuticals USA. Baxter has said it relies on a contract plant in Germany where federal inspectors previously found sterility problems.
Sarcoma Patients Carry the Largest Share of the Risk
The label understates who is affected, and that gap is the central fact for readers.
Ifosfamide is FDA-approved only for malignant germ cell testicular cancer, in combination with other agents, in patients who have already received at least two prior chemotherapy regimens. That is a narrow indication covering a small number of people, as described in the National Cancer Institute's drug listing.
In practice, the drug reaches much further. It is a component of curative regimens for bone and soft-tissue sarcomas, in which alternatives are limited. It is also part of a common salvage regimen for relapsed diffuse large B-cell lymphoma, which means the shortage touches more patients than the two cancers usually named. Sarcomas are relatively rare, so the patient population is small in absolute terms but has few fallback options.
The drug is typically given alongside mesna, a protective agent that reduces the risk of bladder bleeding and inflammation. That pairing is standard and does not substitute for ifosfamide itself.
The people facing the most immediate consequence are patients mid-regimen. A delayed cycle is not equivalent to a missed dose of a maintenance medication. Chemotherapy schedules are built around specific intervals, and interruptions can affect how well a regimen works, though the size of that effect depends on the cancer, the regimen, and the length of delay. Patients at smaller community practices may face more constrained supply than those at large academic centers, which have greater purchasing leverage.
Import Authorization and Dose Rounding as Stopgaps
Several mitigation measures are underway, none of which resolves the underlying manufacturing problem.
ASCO has directed practices to its Drug Shortages Resource Center, which compiles clinical mitigation guidance, dose rounding protocols and supply updates, and has pointed clinicians toward waste minimization guidance from a federal emergency preparedness program. Dose rounding means adjusting a calculated dose slightly to match available vial sizes so that partial vials are not discarded, a practice that can stretch supply meaningfully across a practice.
The FDA has said it plans to temporarily allow importation of ifosfamide from overseas manufacturers that do not normally supply the U.S. market. The agency has used that mechanism to relieve prior oncology shortages. Imported product typically arrives with foreign labeling, which requires additional handling procedures at the pharmacy level.
Manufacturer timelines have shifted repeatedly. Baxter has estimated that some of its presentations may return in October, with others expected earlier. Fresenius Kabi has pointed to a late-summer release for its one-gram vials, and Hikma has estimated late September or early October for presentations on backorder. Those are estimates rather than commitments, and several have already moved once.
Questions Patients Can Raise with Their Oncology Team
Nobody receiving ifosfamide should change or stop treatment based on this news. Supply decisions are made at the practice level and depend on inventory a patient cannot see.
What patients and families can reasonably ask is whether their practice currently has ifosfamide on hand for their scheduled cycles, what the plan is if a cycle cannot be given on time, whether a referral to another center with supply is an option, and whether they are candidates for a clinical trial. Asking these questions early is more useful than asking after a cycle has already been postponed.
Anyone told a treatment will be delayed should ask specifically what the delay means for their regimen, since the answer varies. For some cancers, a short delay carries little consequence. For others it matters more. That is a conversation with a treating oncologist, not something to resolve from general information.
Several things remain unresolved. Whether the October recovery estimate holds is unknown. The FDA has not announced which overseas manufacturers will be authorized or when product will arrive. No national data show how many patients have had treatment delayed. And the underlying pattern is familiar: sterile injectable generics with thin margins and few manufacturing sites have repeatedly fallen into shortage, suggesting this will not be the last such alert. MedicalDaily will report when the FDA updates its shortage listing or announces an import authorization.
Key Questions Answered
What did ASCO warn about? Critical supply disruptions affecting ifosfamide, with some oncology practices reporting less than a few weeks of inventory on hand and no direct substitute available.
Which patients use this drug? It is FDA-approved only for previously treated malignant germ cell testicular cancer, but it is also used in regimens for bone and soft tissue sarcomas and in a salvage regimen for relapsed lymphoma.
What caused the shortage? The FDA cites requirements to comply with good manufacturing practices at one manufacturer, along with increased demand on two others.
How long is it expected to last? One manufacturer has estimated October for some presentations. Those estimates are not guarantees and have moved before.
What is being done? ASCO has issued guidance on dose rounding and waste minimization, and the FDA plans to temporarily allow imports from overseas manufacturers.
Should a patient change treatment? No. Supply decisions are made at the practice level. Patients should ask their oncology team about inventory and contingency plans rather than altering anything themselves.
What should a patient ask if a cycle is delayed? What the delay means specifically for their regimen and cancer type, and whether transfer to another center or a clinical trial is an option.
